

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**ZJ**

**中基長壽科學**

ZHONG JI LONGEVITY SCIENCE

**Zhong Ji Longevity Science Group Limited**

**中基長壽科學集團有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 767)**

**CHANGE OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER**

The Board announces that with effect from 8 December 2021:

**CHANGE OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER**

Due to the business development of the Group, Mr. WANG Hongxin has been re-designated as the Chief Investment Officer and chairman of the China Region to oversee the Group's business in Mainland China, and has ceased to act as an executive Director and the Chief Executive Officer.

Mr. LI Jiuhua has been appointed as an executive Director and the Chief Executive Officer.

**CHANGE OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Zhong Ji Longevity Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, due to the business development of the Group, Mr. WANG Hongxin has been re-designated as the Chief Investment Officer and chairman of the China Region to oversee the Group's business in Mainland China, and has ceased to act as an executive Director and the Chief Executive Officer, with effect from 8 December 2021.

Mr. Wang has confirmed to the Board that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

The Board is pleased to announce that Mr. LI Jiuhua (“**Mr. Li**”) has been appointed as an executive Director and the Chief Executive Officer of the Company with effect from 8 December 2021.

The biographical details of Mr. Li are set out below:

Mr. Li, aged 58, graduated from the Xiamen University in the PRC with a bachelor degree in Finance in 2003 and obtained a master degree in Business Administrative from the Jiangxi University of Finance and Economics in the PRC in 2011. Mr. Li has over 34 years of experience in the securities and finance industries. From March 2017 to August 2017, he was the deputy chief executive officer of China Huarong International Holdings Limited, a subsidiary of China Huarong Asset Management Co., Ltd. (a company listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (stock code: 2799)). He was formerly appointed as an executive Director of the Company in September 2017, the Chief Executive Officer of the Company in October 2017, an authorized representative of the Company and a member of the remuneration Committee of the Board in February 2018 and had resigned from all positions in the Company in January 2020. He served as the chairman of Zhong Bang International Holdings Limited and the assistant to general manager for Jiangxi Ganjiang Traditional Chinese Medicine Branch Chuangcheng Construction Investment Group Co., Ltd. (江西贛江中醫藥科創城建設投資集團有限公司) from February 2020 to November 2021.

As at the date of this announcement, save as aforesaid, Mr. Li has confirmed that he (i) does not have any relationship with any Director, senior management, or substantial or controlling shareholder (as defined in the Rules Governing the Listing of Securities (the “**Listing Rules**”) on the Stock Exchange) of the Company; (ii) does not have, and is not deemed to have, any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) does not hold any other directorship in the last three years in public companies, the securities of which are listed on any securities market in Hong Kong or overseas; and (iv) does not hold any other positions in the Group.

Pursuant to the appointment letter entered into by the Company and Mr. Li, Mr. Li is not appointed for any specific or proposed term of service, but is subject to retirement by rotation and re-election (if applicable) at an annual general meeting at least once every three years in accordance with the bye-laws of the Company and the Corporate Governance Code set out in Appendix 14 to the Listing Rules. He is entitled to receive a director's fee of HK\$100,000 per month, which is determined by the remuneration committee of the Company and the Board and is subject to annual review with reference to the prevailing market rate, his duties and responsibilities in and the time he spent on the affairs of the Company.

Save as disclosed above, there is no other information in relation to the appointment of Mr. Li which is required to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules, and there is no other matter that needs to be brought to the attention of the shareholders of the Company.

The Board would like to welcome Mr. Li for rejoining the Company.

By order of the Board  
**Zhong Ji Longevity Science Group Limited**  
**Yan Li**  
*Chairman*

Hong Kong, 8 December 2021

As at the date of this announcement, the Directors are:

*Executive Directors*

Mr. Yan Li (*Chairman*)  
Mr. Li Jiuhua (*Chief Executive Officer*)  
Mr. Li Xiaoshuang  
Ms. Cao Xie Qiong

*Independent non-executive Directors*

Mr. Tam Ho Leung Simon  
Ms. Wang Weixia  
Mr. Chai Nan

*Non-executive Directors*

Dr. He Yiwu  
Ms. Choi Ngai Wah

*In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.*